Sugi Predict

Sugi Predict / Compounds / SCHEMBL2016511

SCHEMBL2016511

SCHEMBL2016511

CCCCCCCCCCCCCCCCCCOC1CC(COc2ccc(CO)cc2)CC(OCCCCCCCCCCCCCCCCCC)C1OCCCCCCCCCCCCCCCCCC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 0.42
▸ RAB9A P51151 3/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ TP53 P04637 2/20 0.42
▸ GAA P10253 1/20 0.42
▸ NR5A1 Q13285 1/20 0.41
▸ S1PR1 P21453 7/20 0.40
▸ S1PR5 Q9H228 7/20 0.40
▸ S1PR3 Q99500 5/20 0.40
▸ USP2 O75604 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ CASP1 P29466 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ SLCO1B3 Q9NPD5 1/20 0.40
▸ SLCO1B1 Q9Y6L6 1/20 0.40
▸ HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL533766 0.82 LMNA (0.43) TP53NR5A1S1PR1S1PR5S1PR3
SCHEMBL2018351 0.81 CNR2 (0.46) MEN1KMT2AALDH1A1
SCHEMBL31193361 0.81 CNR2 (0.46) MEN1KMT2AALDH1A1
SCHEMBL533740 0.81 MMP9 (0.38) TP53NR5A1ALDH1A1LMNA
SCHEMBL15908216 0.81 MMP9 (0.38) TP53NR5A1LMNAMAPK1SMN1; SMN2
SCHEMBL2020613 0.79 S1PR2 (0.37) S1PR1S1PR5S1PR3S1PR4
SCHEMBL31193427 0.79 CNR1 (0.46) MEN1KMT2ANR5A1ALDH1A1
SCHEMBL2019737 0.79 CNR1 (0.46) MEN1KMT2ANR5A1ALDH1A1
SCHEMBL534408 0.78 SLC2A1 (0.40) NR5A1S1PR1S1PR5S1PR3LMNA
SCHEMBL15908236 0.78 SLC2A1 (0.40) NPC1RAB9ATP53GAANR5A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353147-B2 Method for producing peptide AJINOMOTO CO., INC. (JP) 2016-05-31 — — US claimed
US-9353148-B2 Method for producing peptide AJINOMOTO CO., INC. (JP) 2016-05-31 — — US claimed
US-8859732-B2 Benzylic compound AJINOMOTO CO., INC. (JP) 2014-10-14 — — US claimed
US-20140088291-A1 METHOD FOR PRODUCING PEPTIDE AJINOMOTO CO., INC. (JP) 2014-03-27 — — US claimed
US-20140080999-A1 METHOD FOR PRODUCING PEPTIDE AJINOMOTO CO., INC. (JP) 2014-03-20 — — US claimed
EP-2518041-A1 BENZYL COMPOUND Ajinomoto Co., Inc. (JP) 2012-10-31 — — EP claimed
US-20110160433-A1 BENZYLIC COMPOUND AJINOMOTO CO., INC. (JP) 2011-06-30 — — US claimed
US-12351601-B2 Method for producing peptide continuously AJINOMOTO CO., INC. (JP) 2025-07-08 — — US disclosed
US-20250188118-A1 LIQUID PHASE PEPTIDE SYNTHESIS METHODS AMGEN INC. (US) 2025-06-12 — — US disclosed
WO-2025122535-A2 LIQUID PHASE PEPTIDE SYNTHESIS METHODS AMGEN INC. (US) 2025-06-12 — — WO disclosed
US-11939404-B2 Method for producing cyclized peptide having intramolecular S-S bond AJINOMOTO CO., INC. (JP) 2024-03-26 — — US disclosed
US-20220041648-A1 METHOD FOR PRODUCING PEPTIDE CONTINUOUSLY AJINOMOTO CO., INC. (JP) 2022-02-10 — — US disclosed
EP-3882255-A1 METHOD FOR PRODUCING CYCLIZED PEPTIDE HAVING INTRAMOLECULAR S-S BOND AJINOMOTO CO., INC. (JP) 2021-09-22 — — EP disclosed
US-20140371424-A1 BENZYLIC COMPOUND AJINOMOTO CO., INC. (JP) 2014-12-18 — — US disclosed
US-8859732-B2 Benzylic compound AJINOMOTO CO., INC. (JP) 2014-10-14 — — US disclosed
US-20140296483-A1 METHOD FOR REMOVING FMOC GROUP AJINOMOTO CO., INC. (JP) 2014-10-02 — — US disclosed
US-20140088291-A1 METHOD FOR PRODUCING PEPTIDE AJINOMOTO CO., INC. (JP) 2014-03-27 — — US disclosed
US-20140080999-A1 METHOD FOR PRODUCING PEPTIDE AJINOMOTO CO., INC. (JP) 2014-03-20 — — US disclosed
EP-2518041-A1 BENZYL COMPOUND Ajinomoto Co., Inc. (JP) 2012-10-31 — — EP disclosed
US-20110160433-A1 BENZYLIC COMPOUND AJINOMOTO CO., INC. (JP) 2011-06-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188118-A1 LIQUID PHASE PEPTIDE SYNTHESIS METHODS VIP, RNGTT, SSU72 NPC1 2397/4885RAB9A 4009/4885MEN1 1270/4885
US-20220041648-A1 METHOD FOR PRODUCING PEPTIDE CONTINUOUSLY VIP, NPPA, NGLY1 NPC1 1225/4885RAB9A 4655/4885MEN1 1477/4885
US-20110160433-A1 BENZYLIC COMPOUND VIP, NGLY1, FURIN NPC1 749/4885RAB9A 3092/4885MEN1 109/4885
US-11939404-B2 Method for producing cyclized peptide having intramolecular S-S bond SPPL2B, PTMS, VIP NPC1 4150/4885RAB9A 3157/4885MEN1 844/4885
US-20140080999-A1 METHOD FOR PRODUCING PEPTIDE VIP, ANPEP, NPPA NPC1 1229/4885RAB9A 3512/4885MEN1 1526/4885
US-20140371424-A1 BENZYLIC COMPOUND VIP, NGLY1, FURIN NPC1 749/4885RAB9A 3092/4885MEN1 109/4885
US-20140296483-A1 METHOD FOR REMOVING FMOC GROUP ESD, HM13, FURIN NPC1 2605/4885RAB9A 2589/4885MEN1 337/4885
US-20140088291-A1 METHOD FOR PRODUCING PEPTIDE ANPEP, NPPA, LNPEP NPC1 363/4885RAB9A 3173/4885MEN1 1623/4885
US-12351601-B2 Method for producing peptide continuously VIP, NPPA, NGLY1 NPC1 1225/4885RAB9A 4655/4885MEN1 1477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.